MARKET

ACRX

ACRX

Acelrx Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.060
+0.040
+3.92%
After Hours: 1.060 0 0.00% 18:26 09/24 EDT
OPEN
1.010
PREV CLOSE
1.020
HIGH
1.060
LOW
1.010
VOLUME
516.15K
TURNOVER
--
52 WEEK HIGH
2.940
52 WEEK LOW
0.7500
MARKET CAP
126.33M
P/E (TTM)
-2.9453
1D
5D
1M
3M
1Y
5Y
AcelRx Pharmaceuticals to Participate in Two September Investor Conferences
/PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that management wil...
PR Newswire - PRF · 09/10 19:19
Study Results Announced During Award-Winning Presentation on the Effect of Sufentanil Sublingual Tablet on Outpatient Plastic Surgery at the Annual Miami Cosmetic Surgery Event
/PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the results of a st...
PR Newswire - PRF · 08/30 12:30
AcelRx To Present On Effect Of Administration Of Sufentanil Sublingual Tablet On Reducing Post-Operative Recovery Time And Opioid Use In Plastic Surgery At The Annual Miami Cosmetic Surgery Event Aug. 27
AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today
Benzinga · 08/26 12:32
Presentation on the Effect of the Administration of Sufentanil Sublingual Tablet on Reducing Post-Operative Recovery Time and Opioid Use in Plastic Surgery at the Annual Miami Cosmetic Surgery Event
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced an upcoming presentation on the eff...
PR Newswire · 08/26 12:30
21 Stocks Moving in Thursday's Pre-Market Session
Gainers
Benzinga · 08/19 11:07
34 Stocks Moving In Wednesday's Mid-Day Session
Gainers PharmaCyte Biotech, Inc. (NASDAQ: PMCB) shares jumped 139% to $8.18 after surging over 15% on Tuesday.
Benzinga · 08/18 16:00
The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 17)
Benzinga · 08/18 11:37
--HC Wainwright Adjusts Price Target on AcelRx Pharmaceuticals to $5 From $7, Maintains Buy Rating
MT Newswires · 08/17 10:50
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ACRX. Analyze the recent business situations of Acelrx Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ACRX stock price target is 6.00 with a high estimate of 9.00 and a low estimate of 4.000.
EPS
Institutional Holdings
Institutions: 104
Institutional Holdings: 26.34M
% Owned: 22.10%
Shares Outstanding: 119.18M
TypeInstitutionsShares
Increased
12
715.15K
New
16
1.29M
Decreased
27
11.04M
Sold Out
27
1.98M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.13%
Pharmaceuticals & Medical Research
-1.02%
Key Executives
Non-Executive Chairman/Independent Director
Adrian Adams
Chief Executive Officer/Director
Vincent Angotti
Co-Founder/Director
Pamela Palmer
Chief Financial Officer
Raffi Asadorian
Other
Badri Dasu
Independent Director
Richard Afable
Independent Director
Marina Bozilenko
Independent Director
Mark Edwards
Independent Director
Stephen Hoffman
Independent Director
Howard Rosen
Independent Director
Mark Wan
No Data
About ACRX
AcelRx Pharmaceuticals, Inc is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidates include DSUVIA (known as DZUVEO in Europe) and Zalviso. Its DSUVIA is indicated for use in adults in a certified medically supervised healthcare setting, such as hospitals, surgical centers, and emergency departments, for the management of acute pain. DSUVIA is designed to provide rapid analgesia via a non-invasive route and to eliminate dosing errors associated with IV administration. Its Zalviso is a sufentanil sublingual tablet system intended for the management of moderate-to-severe acute pain in hospitalized adult patients. Zalviso consists of a pre-filled cartridge of 40 sufentanil sublingual tablets, 15 microgram (McG), delivered by the Zalviso System, a needle-free, handheld, patient-administered, pain management system.

Webull offers kinds of AcelRx Pharmaceuticals Inc stock information, including NASDAQ:ACRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ACRX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ACRX stock methods without spending real money on the virtual paper trading platform.